The GenoDiabMar registry. A collaborative research platform of “real world” type 2 diabetes patients - Sierra, Adriana; Otero, Sol; Rodríguez, Eva; Faura, Anna; Vera, María; Riera, Marta; Palau, Vanesa; Durán, Xavier; Costa-Garrido, Anna; Sans, Laia; Márquez, Eva; Poposki, Vladimir; et al. (medRxiv, 2021)
The GenoDiabMar registry is a prospective study aims to provide data on demographic, biochemical and clinical changes, from a “real-world” population of Type 2 DM (T2D) patients. This registry is addressed to find new biomarkers related to the micro and macrovascular complications of T2D, especially focused on diabetic nephropathy. The registry includes longitudinal serum and urine samples, DNA bank, as well as data on 227 metabolomics profiles, 77 Immunoglobulin G glycomics traits and others emerging biomarkers. 650 patients aged 69.56 extpm9.31 with different grades of chronic kidney disease; (G1-2 50.3%, G3 31.4%, G4 10.8% and G5 7.5%) were followed up for 4.96 ( extpm0.43) years. Regardless of albuminuria, women lost 0.93 (0.40-1.46) glomerular filtration units per year less than men. 17% of the participant experienced rapid progression of renal function, 75.2% men, with differential risk factors between sexes; severe macroalbuminuria >300mg/g for men OR[IQ] 2.40 [1.29:4.44] and concomitant peripheral vascular disease 3.32 [1.10:9.57] for women. An overall mortality of 23% was detected (38% due to Cardiovascular aetiology).This cohort is postulated as a great tool for scientific collaboration for studies, whether they are focused on T2D, or whether they are interested in comparing differential markers between diabetic and non-diabetic populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementClara Barrios is funded by grants FIS-FEDER-ISCIII PI16/00620 (Ext 2021) and Strategic Plan for Research and Innovation in Health, CatSalut, PERIS STL008 (2019-2021) to develop clinical and epidemiological studies mainly focused in diabetes and its associations with new biomarkers.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Institut Hospital del Mar d’Investigacions Mediques gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors